Caris Life Sciences publishes results of antibody-drug study in breast cancer

Caris Life Sciences (CAI) published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan, or T-DXd, and sacituzumab govitecan, or SG, in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor, or HR,-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups. However, for patients with HR-negative and HER2-null tumors, SG showed better results when used as the first treatment. For other patient groups, there was no clear advantage to starting with one drug over the other. Caris’ real-world database drew from over 4,000 patients to uncover key differences that have the potential to assist clinicians in choosing treatment options to improve patient care. Additionally, results concluded that T-DXd and SG provided comparable benefits in patients with triple-negative breast cancer, highlighting the need for personalized treatment strategies based on tumor subtype.